Thrombogenicity of Lipoprotein A: Laboratory Study Defining the Prothrombotic Effects of Lipoprotein A

计划入组 20 人 · 首次发布于 2022 年 4 月 15 日

Lipoprotein(a) and Progression of Aortic Stenosis

计划入组 364 人 · 首次发布于 2024 年 10 月 18 日

Elevated Lipoprotein(a) in Hospital Staff

计划入组 2,800 人 · 首次发布于 2024 年 3 月 12 日

Lipoprotein(a)

Lipoprotein a inhibitor (Eli Lilly)

Lipoprotein(a) inhibitor(Shanghai Argo)

A&A SMALL CHANGES HANDYPEOPLE

United States

Novozymes A/S

Denmark

Ambu A/S

Denmark

Lipoprotein(a): The Overlooked Cardiovascular Risk Factor Gaining Clinical Recognition

Lilly's Muvalaplin and Silence's Zerlasiran Show Promise in Lowering Lipoprotein(a) in Phase II Trials

Zerlasiran Shows Significant Lipoprotein(a) Reduction in Phase 2 Trial